News >

POUT Data Show Benefit of Adjuvant Chemotherapy in Patients With UTUC

Ariela Katz
Published: Tuesday, Apr 10, 2018

Alison J. Birtle, MD, MBBS, MRCP, FRCR

Alison J. Birtle, MD, MBBS, MRCP, FRCR
Data from the phase III POUT clinical trial demonstrated that adjuvant platinum-based chemotherapy improves disease-free survival (DFS) and metastasis-free survival (MFS) in patients with upper tract urothelial carcinoma (UTUC). Alison J. Birtle, MD, MBBS, MRCP, FRCR, a consultant clinical oncologist for Lancashire Teaching Hospitals, NHS Foundation Trust in the United Kingdom, presented the results at the 2018 Genitourinary Cancers Symposium.

Additionally, recent data from the EORTC 30994 study also demonstrated an improvement in progression-free survival with adjuvant chemotherapy, although no significant benefit was seen in OS. This trial served as part of the rationale for the phase III POUT trial.
Birtle AJ, Chester JD, Jones RJ, et al. Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). Presented at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA. Abstract 407.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication